Blood test matches ALS patients to supplements in quest to slow disease
NCT ID NCT06429059
Summary
This pilot study tested a personalized approach for ALS (Lou Gehrig's disease). Researchers used a blood analysis platform to categorize 50 participants into one of four biological problem areas linked to ALS. Based on their category, participants received a specific dietary supplement for 6 months to see if it could slow the progression of their symptoms. The goal was to see if matching treatment to a person's specific biology is a useful strategy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center
Durham, North Carolina, 27705, United States
-
Temple University
Philadelphia, Pennsylvania, 19122, United States
Conditions
Explore the condition pages connected to this study.